Madrigal’s MASH Drug Rezdiffra Surpasses Q2 Sales Estimates
Madrigal Pharmaceuticals, Rezdiffra, MASH drug, Q2 earnings, sales estimates, FDA approval, commercial launch, NASH treatment
Precigen Restructures, Reduces CAR-T Efforts Amid Job Cuts
Precigen, CAR-T, restructuring, job cuts, UltraCAR-T, gene therapy, AdenoVerse, PRGN-2012
Amgen Boosts Full-Year Sales Forecast Following Horizon-Driven Revenue Surge
Amgen, full-year sales forecast, Horizon acquisition, revenue growth, pharmaceutical industry
Novo Nordisk’s Wegovy Sales Shortfall: A Rare Setback for the Danish Drugmaker
Novo Nordisk, Wegovy, weight-loss drug, sales shortfall, stock performance, pharmaceutical industry
Amgen’s Horizon Acquisition Fuels Revenue Growth and Advances Obesity Drug MariTide
Amgen, Horizon Therapeutics, MariTide, obesity drug, revenue growth, pharmaceutical acquisition
University of Pennsylvania Sues BioNTech Over Unpaid COVID-19 Vaccine Royalties
University of Pennsylvania, BioNTech, COVID-19 vaccine, patent royalties, lawsuit
Lilly’s Blockbuster GLP-1 Drugs Removed from FDA Shortage List
Lilly, GLP-1, FDA, drug shortage, Mounjaro, Zepbound, tirzepatide
Novo Nordisk Expands Legal Campaign Against Compounders of GLP-1 Drugs
Novo Nordisk, GLP-1 drugs, compounded drugs, legal campaign, patient safety, semaglutide
FDA Approves Servier’s Brain Cancer Drug, Triggering $1 Billion Payout for Agios
FDA approval, Servier, brain cancer drug, Voranigo, Agios Pharmaceuticals, IDH1 and IDH2 mutations, blood-brain barrier, cancer metabolism, royalty payments
Stoke Therapeutics Advances Dravet Syndrome Drug to Phase III Trials After FDA Lifts Partial Clinical Hold
Stoke Therapeutics, Dravet syndrome, Phase III trials, FDA, zorevunersen, SCN1A activator, orphan drug designation, rare pediatric disease designation